WolframESamlowskiMD

Oncology • Las Vegas, NV

Clinical Professor of Medicine at University of Nevada School of Medicine.

Join to view full profile

Dr. Samlowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Samlowski's full profile

Already have an account?

Office
9280 W Sunset Road
Suite 100
Las Vegas, NV 89148
Phone+1 702-952-1251

Fax+1 702-952-1241
Is this information wrong?

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 1981 - 1984
Wayne State University School of MedicineResidency, Internal Medicine, 1978 - 1981
Ohio State University College of MedicineClass of 1978

Certifications & Licensure

UT State Medical License 1981 - 2026
NV State Medical License 2007 - 2025
MI State Medical License 1979 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Vegas Seven Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Desert Companion Castle Connolly, 2011
Join now to see all

Clinical Trials

S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 1999 Nov 01
Completed
Phase 2
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2009 Apr 01
Terminated
Phase 1
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates Start of enrollment: 2009 Apr 01
Terminated
Phase 1
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers Start of enrollment: 2016 Jun 01
Completed
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Start of enrollment: 2012 Aug 01
Unknown status
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

The Effect of Non-Overlapping Somatic Mutations in,,, oron the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melan...
Samlowski, W.> ;Cancers. 2024 Jan 30
Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report.
Claire V Ong, Wolfram Samlowski> ;Frontiers in Oncology. 2024 Jan 1
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Megan Othus, David Mutch, Wolfram Samlowski, Elad Sharon, Gabby Lopez, Melissa Plets, Patel, S., Chae, Y., Dennis, M., Gordon, S., Robinson, W., Ryan, C., Blanke, C., ...> ;Clinical Cancer Research. 2024 Jan 5
Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.
Raquel Wescott, Wolfram Samlowski> ;Current Oncology. 2023 Oct 16
Lack of Influence of Non-Overlapping Mutations in,, oron 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metasta...
Alyssa Panning, Wolfram Samlowski, Gabriel Allred> ;Cancers. 2023 Jul 7
2 citations
Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.
Mark Chang, Wolfram Samlowski, Raul Meoz> ;Oncotarget. 2023 Jul 7
Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission.
Kaviyon Sadrolashrafi, Wolfram Samlowski> ;The Oncologist. 2023 May 8
2 citations
Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.
Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Emilie Scherrer, Mizuho Fukunaga-Kalabis, Clemens Krepler, Ruixuan Jiang> ;Future Oncology. 2022 Oct 1
1 citations
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Wolfram Samlowski, Nicholas J Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S Weber> ;Cancer Medicine. 2023 Feb 1
7 citations
Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data.
Leanne Perez, Wolfram Samlowski, Ruby Lopez-Flores> ;Biomedicines. 2022 May 16
2 citations
Elective Checkpoint Inhibitor Discontinuation in Metastatic Solid Tumor Patients: A Case Series.
Ruby Lopez-Flores, Wolfram Samlowski, Leanne Perez> ;Annals of Case Reports. 2022 Jan 1
4 citations
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Wolfram Samlowski, Camille Adajar> ;BMC Cancer. 2021 Nov 7
9 citations
Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series.
Joshua P. Weissman, Wolfram E Samlowski, Raul Meoz> ;The Oncologist. 2021 Sep 14
23 citations
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Wolfram E. Samlowski, James C. Moon, Merle Witter, Michael B. Atkins, John M. Kirkwood, Megan Othus, Antoni Ribas, Vernon K. Sondak, Lawrence E. Flaherty> ;Cancer Medicine. 2017 Oct 10
3 citations
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
David Gill, David D. Stenehjem, Kinjal Parikh, Joseph Merriman, Arun Sendilnathan, Archana M. Agarwal, Andrew W. Hahn, Sumati Gupta, Srinivas K. Tantravahi, Wolfram E....> ;Ecancermedicalscience. 2016 Sep 29
13 citations
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
David D. Stenehjem, Michael Toole, Joseph Merriman, Kinjal Parikh, Stephanie Daignault, Sarah Scarlett, Peg Esper, Katherine A. Skinner, Aaron M. Udager, Srinivas K. T...> ;Cancer Immunology, Immunotherapy. 2016 Jun 8
38 citations
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients
Carmen Ruiz, Julia Li, Madelyn Luttgen, Anand Kolatkar, Jude Kendall, Edna Flores, Zheng Z. Topp, Wolfram E Samlowski, Edward McClay, Kelly Bethel, Soldano Ferrone, Ja...> ;Physical Biology. 2015 Jan 9
22 citations
A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
David S. Hong, Michael S. Gordon, Wolfram E. Samlowski, Razelle Kurzrock, Nizar M. Tannir, David M. Friedland, David S. Mendelson, Nicholas J. Vogelzang, Erik Rasmusse...> ;Clinical Genitourinary Cancer. 2014 Jun 1
162 citations
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Thinle Chodon, Begonya Comin-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Ta...> ;Clinical Cancer Research. 2014 May 1
243 citations
Clinical cancer advances 2012
Bruce J. Roth, Lada Krilov, Sylvia Adams, Carol Aghajanian, Peter B. Bach, Fadi Braiteh, Marcia S. Brose, Lee M. Ellis, Harry P. Erba, Daniel J. George, Mark R. Gilber...> ;Journal of Clinical Oncology. 2013 Jan 1
32 citations
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targete...
Daniel C. Cho, Thomas E. Hutson, Wolfram E. Samlowski, Peter Sportelli, Brad Somer, Paul D. Richards, Jeffrey A. Sosman, Igor Puzanov, M. Dror Michaelson, Keith T. Fla...> ;Cancer. 2012 Dec 15
18 citations
Recent advances in the understanding of the genetics, etiology, and treatment of Merkel cell carcinoma.
Sreekanth Donepudi, Ronald C. DeConti, Wolfram E. Samlowski> ;Seminars in Oncology. 2012 Apr 1
11 citations
Management of melanoma brain metastases in the era of targeted therapy.
Daniela Gonsalves Shapiro, Wolfram E. Samlowski> ;Journal of Skin Cancer. 2011 Dec 15
20 citations
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2′deoxycytidine (decitabine) are differentially regulated by cell cycle progression
Mazin A. Al-Salihi, Margaret Yu, David M. Burnett, Amanda Alexander, Wolfram E. Samlowski, Frank A. Fitzpatrick> ;Epigenetics. 2011 Aug 1
8 citations
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma.
Zeynep Eroglu, Kevin M. Kong, James G. Jakowatz, Wolfram E. Samlowski, John P. Fruehauf> ;Cancer Chemotherapy and Pharmacology. 2011 Jul 19
Join now to see all

Press Mentions

Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021
Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020

Grant Support

Epigenetic Potentiation Of Interferon Using DecitabineNational Cancer Institute2007–2008
Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2006
Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2005–2006
Southwest Oncology Group (UTAH)National Cancer Institute1993–2003
Toxicity Of Continuous Infusion N Acetyl Cysteine With High Dose IL2National Center For Research Resources1998–2002
Nitric Oxide As A Tumor DefenseNational Cancer Institute1997–1999
Toxicity Of Continuous Infusion N-Acetyl Cysteine With High Dose IL-2National Center For Research Resources1995–1997
Phase II Trial--Il-2 Treatment Of Relapsed Or Refractory ANLLNational Center For Research Resources1996
FACS Vantage Cell SorterNational Center For Research Resources1995
Use Of Sulfhydryl Compounds To Increase IL-2 ActivityNational Cancer Institute1992–1994
Endothelial Cell Toxicity Of Marrow Ablative AgentsNational Cancer Institute1988–1992